Novartis and Molecular Partners Report Inclusion of Ensovibep (MP0420) in NIH-Sponsored ACTIV-3 Trial for the Treatment of COVID 19

Shots:

• The P-III ACTIV-3 trial plan to evaluate the safety & efficacy of Ensovibep (MP0420) vs PBO in 300 patients hospitalized with mild to moderate COVID-19. The first patient dosing is anticipated in Q2’21
• If the ensovibep treatment has a positive benefit/risk profile, the trial will enroll an additional 700 patients. Ensovibep is currently being evaluated in a P-I study and its data supports safety, tolerability and 2-3wks. the half-life of the therapy
• Additionally, the companies plan to initiate a global P- II/III EMPATHY study of Ensovibep in Q2’21. The study will enroll 2,000+ patients in the ambulatory setting

Click here ­to­ read full press release/ article | Ref: Molecular Partners | Image: Swiss Biotech Association